{"id":13308,"date":"2020-04-22T13:37:00","date_gmt":"2020-04-22T17:37:00","guid":{"rendered":"https:\/\/geiselmed.dartmouth.edu\/news\/?p=13308"},"modified":"2020-04-22T14:09:02","modified_gmt":"2020-04-22T18:09:02","slug":"researchers-discover-a-key-to-the-survival-of-dormant-breast-cancer-cells","status":"publish","type":"post","link":"https:\/\/geiselmed.dartmouth.edu\/news\/2020\/researchers-discover-a-key-to-the-survival-of-dormant-breast-cancer-cells\/","title":{"rendered":"Researchers Discover a Key to the Survival of Dormant Breast Cancer Cells"},"content":{"rendered":"<p>Most breast cancers utilize the female hormone estrogen to grow, so drug-induced estrogen deprivation is used as a treatment in many patients. However, cancer will recur in one-third of these patients. A research team at Dartmouth\u2019s and Dartmouth-Hitchcock\u2019s Norris Cotton Cancer Center, led by Todd W. Miller, PhD, is trying to understand why dormant breast cancer cells survive despite being starved of estrogen. The team discovered that an anti-diabetes drug, metformin, which is being tested in many clinical trials as an anti-cancer agent, actually activated fat metabolism that protected dormant breast cancer cells during estrogen deprivation. The findings suggest that the drug has context-dependent effects on cancer cells. The results, entitled \u201cAMPK activation by metformin promotes survival of dormant ER+ breast cancer cells,\u201d are newly published online in <em><i>Clinical Cancer Research<\/i><\/em>, a journal of the American Association for Cancer Research.<\/p>\n<p><a href=\"https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-13309\" src=\"https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-130x130.jpg\" alt=\"\" width=\"180\" height=\"180\" srcset=\"https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-130x130.jpg 130w, https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-110x110.jpg 110w, https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-360x360.jpg 360w, https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-55x55.jpg 55w, https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-1600x1600.jpg 1600w, https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-800x800.jpg 800w, https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/image_Miller-580x580.jpg 580w\" sizes=\"auto, (max-width: 180px) 100vw, 180px\" \/><\/a>Metformin activates AMPK, which is a metabolic sensor that signals cells to make energy. Miller\u2019s team found that breast cancer cells survived estrogen deprivation through activation of AMPK. \u201cA major output of AMPK is activation of fat breakdown to produce energy, which we observed in dormant cancer cells,\u201d says Miller. \u201cDrugs that block fat breakdown are used to treat patients with angina (chest pain). Treatment of mice with anti-angina drugs decreased dormant cancer cell numbers.\u201d<\/p>\n<p>Knowledge that metformin has context-dependent effects on cancer cells will inform a better understanding of ongoing and prior clinical trials testing metformin, and help shape the design of trials moving forward. \u201cOur study indicates that the development of drugs targeting fat metabolism is warranted for breast cancer. Most excitingly, anti-angina drugs that block fat metabolism may be quickly repurposed as potential treatments for cancer and tested in clinical trials,\u201d says Miller.<\/p>\n<p>Next steps include clinical trials testing drugs that block fat metabolism in breast cancer. \u201cWe\u2019re also designing preclinical studies to further dissect the roles of fat metabolism in breast and other cancers, with the goal of identifying more refined therapeutic targets that will selectively kill cancer cells and not harm healthy cells,\u201d notes Miller.<\/p>\n<p><strong><em><b><i>Todd W. Miller, PhD, <\/i><\/b><\/em><\/strong><em><i>is Co-Director of the Cancer Biology &amp; Therapeutics Research Program and Scientific Director of the Comprehensive Breast Program at Dartmouth\u2019s and Dartmouth-Hitchcock\u2019s Norris Cotton Cancer Center, and Associate Professor of Molecular and Systems Biology at the Geisel School of Medicine at Dartmouth. His research interests include identification of cancer signaling pathways and the development of targeted therapies for breast and other cancers.<\/i><\/em>\u00a0<a href=\"https:\/\/geiselmed.dartmouth.edu\/miller\/\">geiselmed.dartmouth.edu\/miller<\/a>\u00a0@DartmouthLab<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A common anti-diabetes drug being tested in many clinical trials as an anti-cancer agent activated fat metabolism that promoted the survival of dormant breast cancer cells, suggesting that the drug has context-dependent effects on cancer cells.<\/p>\n","protected":false},"author":143,"featured_media":13321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1,182],"tags":[175,957,847,176],"class_list":["post-13308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-press-release-news","tag-breast-cancer","tag-cancer-research","tag-home-feature","tag-nccc","author-143"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-content\/uploads\/sites\/2\/2020\/04\/Miller_featured2.jpg","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p4r3h1-3sE","_links":{"self":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/13308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/users\/143"}],"replies":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/comments?post=13308"}],"version-history":[{"count":4,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/13308\/revisions"}],"predecessor-version":[{"id":13314,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/13308\/revisions\/13314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/media\/13321"}],"wp:attachment":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/media?parent=13308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/categories?post=13308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/tags?post=13308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}